1. INTRODUCTION {#acm212475-sec-0005}
===============

MR imaging provides excellent soft tissue contrast without the imaging dose associated with CT and Cone Beam CT (CBCT). Improvements in soft tissue contrast are desirable for a number of treatment sites, particularly those where the CBCT imaging may be poor, i.e., pelvis or abdominal tumours.[1](#acm212475-bib-0001){ref-type="ref"} To enable MR imaging prior to and during treatment, the MR‐Linac[2](#acm212475-bib-0002){ref-type="ref"} (Elekta, AB, Stockholm, Sweden) from The MR‐Linac Consortium has combined a 1.5 T Philips scanner (Best, The Netherlands) and a 7 MV Elekta linac.

The presence of a 1.5 T magnetic field (B‐field) in the MR‐Linac during beam delivery results in the Lorentz force acting on the secondary electrons, causing them to follow a spiral trajectory. This results in electrons leaving a tissue‐air boundary to be incident again on the exit surface, a process called the Electron Return Effect (ERE)[3](#acm212475-bib-0003){ref-type="ref"} which can cause a significant increase in the dose to the exit point, for example at the patient\'s skin or internal air cavities. Which can result in increases of up to 56% for a single beam at highly oblique surfaces.[4](#acm212475-bib-0004){ref-type="ref"} The B‐field also influences the path of the electrons in tissue with differences seen in the percentage depth dose curves and field profiles.[3](#acm212475-bib-0003){ref-type="ref"} However, despite these effects, when the planning system accounts for the ERE clinically acceptable plans can be created. This is possible as the Monte Carlo (MC) algorithm accurately models the dose caused by the ERE, which can then be accounted for and removed by the modulation of the fields when IMRT is utilized.[4](#acm212475-bib-0004){ref-type="ref"}, [5](#acm212475-bib-0005){ref-type="ref"}, [6](#acm212475-bib-0006){ref-type="ref"}

Planning studies have been conducted for rectum[7](#acm212475-bib-0007){ref-type="ref"} and lung SBRT[5](#acm212475-bib-0005){ref-type="ref"} leading to clinically acceptable plans, this has also been shown for pancreatic, head and neck, breast, and lung cases,[6](#acm212475-bib-0006){ref-type="ref"} where optimising including the B‐field was shown to remove the effects of the ERE.

Plan creation for the MR‐Linac will utilize the Monaco treatment planning system (Elekta AB, Stockholm, Sweden), which uses a two‐stage method to optimize the dose.[8](#acm212475-bib-0008){ref-type="ref"} The first stage is fluence optimisation and the second is segment shape optimisation. The dose calculation in the second stage is always MC which includes the effect of the 1.5 T B‐field in the dose calculation using the GPUMCD algorithm[9](#acm212475-bib-0009){ref-type="ref"} and has been shown to produce acceptable results when compared against GEANT4.[10](#acm212475-bib-0010){ref-type="ref"} However, for the first stage of the optimisation the user has the option to use either a Pencil Beam (PB) or the MC algorithm. The PB algorithm does not account for the B‐field, but has the benefit of being very fast, whereas the MC algorithm will account for the B‐field but is much slower.

It is unknown whether using MC in the first stage (i.e., accounting for the B‐field) improves the final plan quality or if we can use the PB algorithm in stage 1 and recover the plan, accounting for the B‐field, in stage 2 only. The latter option could save a significant amount of time in plan creation. Therefore, it is the purpose of this paper to compare plan quality for plans optimized in stage 1 with PB with those optimized with the MC algorithm. Additionally, a comparison of the MUs required for each plan as a surrogate for plan complexity[11](#acm212475-bib-0011){ref-type="ref"}, [12](#acm212475-bib-0012){ref-type="ref"} and the total time taken to optimize using each method will be compared.

2. MATERIALS AND METHODS {#acm212475-sec-0006}
========================

2.A. Patient selection {#acm212475-sec-0007}
----------------------

Ten head and neck, ten lung and five prostate patients, all treated curatively at the authors institution, were randomly selected from the clinical archive. All target volumes and organs at risk (OAR) had been delineated at the time of planning by a radiation oncologist specialising in the relevant treatment site.

2.B. Choice of segmentation parameters {#acm212475-sec-0008}
--------------------------------------

To investigate whether the choice of segmentation parameters could significantly affect the results, a range of segmentation parameters were investigated for a representative lung plan. A lung plan was chosen as this treatment site would, potentially, show a larger effect from the ERE due to the greater number of air‐tissue interfaces. The following parameters were varied: minimum segment area, minimum segment width, minimum MU per segment and maximum number of segments per plan. Three combinations were tested, aiming to cover the range of likely optimisation parameters used clinically. One allowed small segments and 180 segments per plan, one only allowed large segments and only 60 segments per plan, whilst the final test had intermediate parameters (Table [1](#acm212475-tbl-0001){ref-type="table"}).

###### 

For a representative lung patient showing the segment parameters used to test the sensitivity to these for the results obtained. The parameters in bold are the ones selected for plan optimisation of the lung plans

  Segment test                   Complex   Intermediate   Simple
  ------------------------------ --------- -------------- --------
  Minimum segment area (cm^2^)   3.0       **9.0**        12.0
  Minimum segment width (cm)     0.5       **0.5**        1.0
  Minimum MU/segments            3.0       **3.0**        4.0
  Maximum \# of seg per plan     180       **90**         60
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2.C. Creation of treatment plans {#acm212475-sec-0009}
--------------------------------

For plan optimisation a research version of Monaco was used in conjunction with an MR‐Linac specific beam model. For the head and neck (H&N) plans Monaco v5.19.00 was used and for the lung and prostate plans Monaco v5.19.02 was utilized, all optimized as 7‐field step and shoot IMRT. Head and neck plans were prescribed to 6600 cGy in 30 fractions, lung plans to 5500 cGy in 20 fractions and the prostate plans to 6000 cGy in 20 fractions. Final dose calculations were performed with a 1% statistical uncertainty with the GPUMCD algorithm and accounting for the 1.5 T B‐field.[9](#acm212475-bib-0009){ref-type="ref"} Plans were optimized to meet the standard clinical departmental constraints for target coverage and OAR doses.

For each patient, the first plan was fully optimized using the PB algorithm for the fluence optimisation (stage 1). The second plan was optimized using the same objective functions and the GPUMCD algorithm for the fluence optimisation stage. Both optimisation arms performed a GPUMCD optimisation as standard in stage 2. This process was automated utilising Elekta\'s research automation toolkit which is an API allowing the software to communicate with the Monaco user interface. All calculation and segmentation parameters were kept constant between plans; details of these are shown in Table [2](#acm212475-tbl-0002){ref-type="table"}. This ensures that the plan comparison is between the stage 1 dose calculation and is not influenced by the objective functions or optimisation parameters.

###### 

Calculation and segmentation parameters for the three different tumour sites

                                        H&N             Lung            Prostate
  ------------------------------------- --------------- --------------- ---------------
  Beam model                            ElektaMRLv509   ElektaMRLv519   ElektaMRLv519
  Energy                                8 MV FFF        7 MV FFF        7 MV FFF
  Grid spacing (cm)                     0.3             0.3             0.3
  Statistical uncertainty Stage 1 (%)   3               3               3
  Statistical uncertainty Stage 2 (%)   1               1               1
  Minimum segment area (cm^2^)          2.0             9.0             5.0
  Minimum segment width (cm)            0.5             0.5             1.0
  Minimum MU/segment                    4.0             3.0             4.0
  Maximum \# segments per plan          90              90              80
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2.D. Analysis of results {#acm212475-sec-0010}
------------------------

The relevant dose statistics to the PTVs and the OARs important for each site were recorded, as documented in Table [3](#acm212475-tbl-0003){ref-type="table"}. For each of the sites the maximum dose to 2 cc of the skin, defined here as a 5 mm contraction from the external contour, was extracted. Due to the potential increase in dose at the lung‐tissue interface the maximum 2 cc dose to the lung surface was extracted, defined as a 5 mm thick layer around the inside of the lung contour. A planning risk volume (PRV) was used around the spinal cord and brainstem, where applicable, expanding isotropically by 5 mm. A copy of the PTV was created which excluded any volume outside the skin contracted by 5 mm, to remove the influence of the build‐up region near the patient\'s skin (PTV IMRT).

###### 

DVH parameters and structures extracted for each of the treatment sites investigated

  H&N                            Lungs                     Prostate   
  ----------------- ------------ -------------- ---------- ---------- ------------
  PTV IMRT          D95%         PTV IMRT       D98%       PTV IMRT   D95%
  Spinal Cord PRV   1 cc (Max)   PTV IMRT       D2%        PTV        2 cc (min)
  Brainstem PRV     1 cc (Max)   Lung           Mean       PTV        2 cc (max)
  Lt/Rt Parotid     Mean dose    Lung           V5         Rectum     2 cc (min)
  Larynx            Mean dose    Lung           V10        Rectum     2 cc (max)
  Skin              Max 2 cc     Lung           V20        Rectum     Mean
                                 Lung           V30        Rectum     V30
                                 Heart          V10        Rectum     V40
                                 Heart          V20        Skin       Max 2 cc
                                 Heart          V30                   
                                 Heart          V40                   
                                 Lung Surface   Max 2 cc              
                                 Skin           Max 2 cc              
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The magnitude of the change in dose to the target and OARs between the two algorithms was compared. The results are presented as box and whisker plots with the boxes marking the 5^th^ and 95^th^ percentiles, the band marks the median, the whiskers mark the maximum and minimum values and the stars indicate the mean value. A paired t‐test was performed between the PB and MC dosimetric statistics to highlight any statistically significant differences.

The time taken to optimize each plan was measured, from initiating stage 1 optimisation to the end of the dose calculation, to assess the usability of each method. Additionally, the total number of MUs was also recorded to provide an estimate of deliverability.[11](#acm212475-bib-0011){ref-type="ref"}

3. RESULTS {#acm212475-sec-0011}
==========

Different segmentation parameters were tested for a representative lung plan. Table [4](#acm212475-tbl-0004){ref-type="table"} shows that the number of MUs was much greater for plans that allowed more segments but the MUs were not significantly (*P* \< 0.01) different between PB and MC for any choice of segmentation parameters. Additionally, regardless of choice of segmentation parameters the time taken using the MC algorithm was always much larger but decreases from being 20 times larger to 6 times larger going from complex to more simple segments. The variation in the DVH parameters for the target and OARs can be seen in Table [5](#acm212475-tbl-0005){ref-type="table"}. The differences between using the PB and MC algorithms for the three different segmentation parameters are all below 2% and mostly below 1%, highlighting that segmentation parameters have a small effect on the outcome of this comparison.

###### 

Time and MU results for three segmentation parameter choices used for a Lung plan. The intermediate segment parameters were utilized for the rest of the patients, these are highlighted in bold

  Segmentation test          Complex   Intermediate   Simple
  -------------------------- --------- -------------- --------
  MU                                                  
  PB‐MC                      1320.1    **1110.2**     869.5
  MC‐MC                      1530.7    **1138.6**     889.05
  Optimisation time (mins)                            
  PB‐MC                      20.08     **17.35**      14.14
  MC‐MC                      149.86    **192.71**     81.21
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###### 

DVH parameters for the PTV IMRTs, both lungs, heart, skin and lung surface for the three different segmentation parameter choices used (see Table [1](#acm212475-tbl-0001){ref-type="table"}) for a representative lung plan. Differences above 1% are highlighted in red/italics. The intermediate segment parameters were utilized for the rest of the patients, these are highlighted in bold

                                  Complex   Intermediate   Simple                                                                
  ------------------------------- --------- -------------- ------------ ------------ ------------ ------------ -------- -------- ------------
  PTV IMRT 98% (cGy)              5359.8    5388.4         *−*0.8       **5320.3**   **5365.2**   *−*0.5       5267.7   5337.8   ***−1.3***
  PTV IMRT 2% (cGy)               5636.2    5614.2         0.5          **5647.3**   **5621.2**   0.4          5666.4   5633.4   0.6
  Lungs V5 Gy (%)                 58.7      58.9           *−*0.4       **58.8**     **59.2**     *−*0.2       59.9     59.2     0.7
  Lungs V10 Gy (%)                51.2      51.7           *−*0.7       **51.2**     **51.9**     *−*0.5       52.3     52.0     0.4
  Lungs V20 Gy (%)                25.6      26.4           *−*0.8       **25.7**     **26.5**     *−*0.8       26.5     26.5     0.1
  Lungs V30 Gy (%)                9.5       9.7            *−*0.2       **9.5**      **9.7**      *−*0.3       9.6      9.6      0.0
  Mean dose to both lungs (cGy)   1327.1    1347.6         ***−1.8***   **1324.3**   **1348.4**   ***−1.5***   1349.6   1347.7   0.1
  Heart V10 Gy (%)                32.9      33.4           *−*0.5       **33.2**     **33.7**     *−*0.5       34.0     33.8     0.2
  Heart V20 Gy (%)                24.8      25.6           *−*0.8       **25.1**     **25.9**     *−*0.8       25.9     26.5     −0.6
  Heart V30 Gy (%)                18.0      18.5           *−*0.4       **17.9**     **18.3**     *−*0.5       18.2     19.0     −0.8
  Heart V40 Gy (%)                12.4      12.6           *−*0.1       **12.4**     **12.5**     *−*0.2       12.8     13.0     −0.1
  Skin 2 cc (max) (cGy)           2653.4    2651.3         ***1.2***    **2619.7**   **2588.0**   0.1          2581.2   2547.5   ***1.3***
  Lung Surface 2 cc (max) (cGy)   5635.6    5611.6         0.5          **5645.8**   **5615.5**   0.4          5660.0   5630.8   0.5
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The average MUs and optimisation time over the number of patients planned for each treatment group are shown in Table [6](#acm212475-tbl-0006){ref-type="table"}. This shows the average time taken to optimize using the PB and MC algorithms, as well as the average number of MUs. The standard deviation is shown in parentheses.

###### 

The mean and standard deviation in the number of MUs and time taken to optimise the plans is shown. The two different algorithms used for the fluence optimisation stage, PB and MC are shown for three different anatomical sites. The *P*‐values for a paired t‐test are also shown in bold

  Mean (SD)                  Patient group                     
  -------------------------- ---------------- ---------------- ----------------
  Monitor units (MU)                                           
  PB                         1494.6 (152.9)   1377.4 (328.5)   1508.8 (105.3)
  MC                         1517.9 (169.9)   1410.4 (328.4)   1553.7 (173.2)
  * P*‐value                 **0.63**         **0.17**         **0.24**
  Optimisation time (mins)                                     
  PB                         38.9 (15.8)      24.9 (7.3)       29.7 (2.5)
  MC                         480.4 (176.9)    296.7 (136.3)    263.2 (77.9)
  * P*‐value                 **≪0.001**       **0.001**        **0.002**
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Table [6](#acm212475-tbl-0006){ref-type="table"} shows that the number of MUs delivered with plans optimized with PB and MC for stage 1 are not significantly different for any of the treatment sites investigated. This indicates that the plans would take no longer to deliver or are no more complex in either arm. However, the difference in times it takes to optimize the plans is highly significant. It takes approximately ten times longer to optimize a plan using MC for stage 1 than it does with PB for stage 1. For head and neck plans the differences increase to over 12 times longer but for prostate plans this is 9 times longer.

The DVH parameters evaluated (Table [3](#acm212475-tbl-0003){ref-type="table"}) for lung patients with the PB and MC algorithm are shown in Fig. [1](#acm212475-fig-0001){ref-type="fig"}. Figures [2](#acm212475-fig-0002){ref-type="fig"} and [3](#acm212475-fig-0003){ref-type="fig"} show the same data for ten head and neck patients, and five prostate patients respectively.

![DVH parameters for ten lung patients optimized with a PB algorithm (thin black lines) and MC algorithm (thick red lines) for fluence optimisation. The boxes mark the 5^th^ and 95^th^ percentiles, the band marks the median, stars mark the mean and the whiskers mark the maximum and minimum values. A \* indicates a significance of *P *\<* *0.01.](ACM2-20-43-g001){#acm212475-fig-0001}

![DVH parameters for ten H&N patients optimized with a PB algorithm (thin black lines) and MC algorithm (thick red lines) for fluence optimisation. The boxes mark the 5^th^ and 95^th^ percentiles, the band marks the median, stars mark the mean and the whiskers mark the maximum and minimum values. A \* indicates a significance of *P *\<* *0.01.](ACM2-20-43-g002){#acm212475-fig-0002}

![DVH parameters for five prostate patients optimized with a PB algorithm (thin black lines) and MC algorithm (thick red lines) for fluence optimisation. The boxes mark the 5^th^ and 95^th^ percentiles, the band marks the median, stars mark the mean and the whiskers mark the maximum and minimum values.](ACM2-20-43-g003){#acm212475-fig-0003}

Most parameters showed with little difference between the two optimisation arms. The DVH parameters that showed statistically significant difference (at *P* \< 0.01 which was chosen due to the low number of patients) are denoted in the plots with a \*. The H&N patients show a significant difference for the maximum dose to 2 cc of the skin, with the PB plans being 1.3% higher which is not considered clinically significant. The prostate plans showed no significant differences between the optimisation arms.

Some parameters were statistically significant for the lung cases but these were not considered clinically significant on discussion with a consultant oncologist. Specifically, a difference for the Heart V10 was seen of 2.4%, with the MC arm showing a higher dose. Figure [4](#acm212475-fig-0004){ref-type="fig"} shows the DVHs for a representative lung patient optimized with a PB algorithm (thick lines) and MC algorithm (dashed lines) for fluence optimisation.

![DVHs for a representative lung patient optimized with a PB algorithm (thick lines) and MC algorithm (dashed lines) for fluence optimisation (stage 1).](ACM2-20-43-g004){#acm212475-fig-0004}

4. DISCUSSION {#acm212475-sec-0012}
=============

This work has investigated the effect of using PB or MC algorithms for fluence optimisation in creating plans with Monaco for the MR‐Linac for multiple sites. The presence of the B‐field results in the ERE, that is only reproduced with the MC dose calculation. However, using a MC dose calculation will take a significantly longer time in an optimisation process compared to PB. This work has demonstrated that there were no clinically significant changes in the DVH parameters between using the two algorithms for the first stage of the optimisation. Nonetheless there is a large increase (\~10 times) in the time taken to optimize when using the MC algorithm. Only five parameters showed a statistically significant dosimetric difference between plans produced using the MC or PB algorithms. These differences between the arms were all less than 2.5% and on discussion with a consultant oncologist were not considered clinically important.

This work has investigated two optimisation arms, PB or MC, for head and neck plans, lung plans and prostate plans to cover a range of anatomical sites with varying amounts of inhomogeneities present. Interestingly, even the lung plans showed minimal differences between the optimisation arms. Because of the large inhomogeneities and tissue/air interfaces it was expected that using the MC algorithm for fluence optimisation would work better as it accounts for the B‐field and associated ERE during optimisation. There were statistically significant differences for four of the DVH parameters for the lung plans but none of these were considered clinically significant. Apparently the changes in dose distribution due to ERE are so localized that the segment weight optimization in the second stage, where MC accounting for the B‐field was used, could fully recover the plan quality.

Several papers have shown that Monaco is capable of producing clinically acceptable plans for linacs with a 1.5 T B‐field.[5](#acm212475-bib-0005){ref-type="ref"}, [6](#acm212475-bib-0006){ref-type="ref"}, [7](#acm212475-bib-0007){ref-type="ref"} However, to our knowledge none have investigated the effect of the fluence optimisation method on plan quality. This is the first paper to investigate whether the choice of algorithm in the first stage of optimisation makes a difference on plan quality for the MR‐Linac. The results obtained here could also be true at 0 T, applicable for standard linacs but this has not been investigated here.

One of the limitations of this study was that the segmentation parameters were kept constant for each plan site. We initially tested several sets of parameters for a lung plan. Changing from 60 to 180 segments per plan, as well as from 3 cm^3^ to 12 cm^3^ for the minimum segment area kept differences between PB and MC algorithms below 1% for most DVH parameters, with only 5 parameters between 1% and 2%. Therefore, we believe that the choice of segmentation parameters does not change the overall conclusion. We have investigated head and neck, thorax and pelvis regions to have a range of anatomy, and since in all three the first stage optimization made no difference we expect this conclusion to hold for further treatment sites.

The number of MUs has been used as a surrogate measure for complexity and whilst other metrics have been proposed,[12](#acm212475-bib-0012){ref-type="ref"} the number of MUs is still thought to give an indication of the complexity of a plan[11](#acm212475-bib-0011){ref-type="ref"}, [12](#acm212475-bib-0012){ref-type="ref"} and is easily extracted from the plans. The optimisation method showed no significant difference in the plan MU, indicating no measurable difference in complexity between plans.

This work illustrates that using the faster PB algorithm for fluence optimisation does not degrade the plan quality or reduce plan deliverability.

5. CONCLUSION {#acm212475-sec-0013}
=============

The MR‐Linac will utilize the Monaco TPS which uses two stages for plan optimisation, stage 1 --- fluence optimisation and stage 2 --- segment optimisation. This investigation has shown that due to increased planning time without significant improvement in plan quality, the use of MC for the fluence optimisation stage is not necessary.
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